Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals

Marie I. Samanovic, Amber R. Cornelius, Jimmy P. Wilson, Trishala Karmacharya, View ORCID ProfileSophie L. Gray-Gaillard, Joseph Richard Allen, Sara Wesley Hyman, Gali Moritz, Mahnoor Ali, View ORCID ProfileSergei B. Koralov, View ORCID ProfileMark J. Mulligan, View ORCID ProfileRamin Sedaghat Herati
doi: https://doi.org/10.1101/2021.02.07.21251311
Marie I. Samanovic
1NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amber R. Cornelius
1NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jimmy P. Wilson
1NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trishala Karmacharya
1NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie L. Gray-Gaillard
1NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sophie L. Gray-Gaillard
Joseph Richard Allen
1NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Wesley Hyman
1NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gali Moritz
1NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahnoor Ali
1NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergei B. Koralov
2Department of Pathology, New York University School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sergei B. Koralov
Mark J. Mulligan
1NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark J. Mulligan
  • For correspondence: ramin.herati@nyulangone.org mark.mulligan@nyulangone.org
Ramin Sedaghat Herati
1NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ramin Sedaghat Herati
  • For correspondence: ramin.herati@nyulangone.org mark.mulligan@nyulangone.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The advent of COVID-19 vaccines will play a major role in helping to end the pandemic that has killed millions worldwide. Vaccine candidates have demonstrated robust humoral responses and have protected against infection. However, efficacy trials were focused on individuals with no prior exposure to SARS-CoV-2, and, as a result, little is known about immune responses induced by these mRNA vaccines in individuals who recovered from COVID-19. Here, we evaluated immune responses in 32 subjects who received two-dose BNT162b2 mRNA vaccination. In individuals naive to SARS-CoV-2, we observed robust increases in humoral and antigen-specific antibody-secreting cell (ASC) responses following each dose of vaccine, whereas individuals with prior exposure to SARS-CoV-2 demonstrated strong humoral and antigen-specific ASC responses to the first dose but muted responses to the second dose of the vaccine for the time points studied. These data highlight an important gap in our knowledge and may have major implications for how these vaccines should be used to prevent COVID-19.

One sentence summary Immune responses to the booster dose of mRNA vaccine BNT162b2 are poor in subjects with a prior history of SARS-CoV-2 infection.

Competing Interest Statement

MJM reported potential competing interests: laboratory research and clinical trials contracts with Lilly, Pfizer (exclusive of the current work), and Sanofi for vaccines or MAB vs SARS-CoV-2; contract funding from USG/HHS/BARDA for research specimen characterization and repository; research grant funding from USG/HHS/NIH for SARS-CoV-2 vaccine and MAB clinical trials; personal fees from Meissa Vaccines, Inc. for Scientific Advisory Board service.

Funding Statement

This work was supported by NIH grants AI114852 and AI082630 (R.S.H), and AI148574 (M.J.M.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Study was performed with approval from the NYU Institutional Review Board (IRB 20-00595 and IRB 18-02037).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data from this study is available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted February 09, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals
Marie I. Samanovic, Amber R. Cornelius, Jimmy P. Wilson, Trishala Karmacharya, Sophie L. Gray-Gaillard, Joseph Richard Allen, Sara Wesley Hyman, Gali Moritz, Mahnoor Ali, Sergei B. Koralov, Mark J. Mulligan, Ramin Sedaghat Herati
medRxiv 2021.02.07.21251311; doi: https://doi.org/10.1101/2021.02.07.21251311
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals
Marie I. Samanovic, Amber R. Cornelius, Jimmy P. Wilson, Trishala Karmacharya, Sophie L. Gray-Gaillard, Joseph Richard Allen, Sara Wesley Hyman, Gali Moritz, Mahnoor Ali, Sergei B. Koralov, Mark J. Mulligan, Ramin Sedaghat Herati
medRxiv 2021.02.07.21251311; doi: https://doi.org/10.1101/2021.02.07.21251311

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (166)
  • Anesthesia (49)
  • Cardiovascular Medicine (447)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (188)
  • Epidemiology (5196)
  • Forensic Medicine (3)
  • Gastroenterology (192)
  • Genetic and Genomic Medicine (746)
  • Geriatric Medicine (76)
  • Health Economics (210)
  • Health Informatics (689)
  • Health Policy (350)
  • Health Systems and Quality Improvement (221)
  • Hematology (98)
  • HIV/AIDS (161)
  • Infectious Diseases (except HIV/AIDS) (5788)
  • Intensive Care and Critical Care Medicine (353)
  • Medical Education (101)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (754)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (140)
  • Occupational and Environmental Health (230)
  • Oncology (473)
  • Ophthalmology (149)
  • Orthopedics (37)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (138)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (135)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (851)
  • Public and Global Health (1983)
  • Radiology and Imaging (340)
  • Rehabilitation Medicine and Physical Therapy (154)
  • Respiratory Medicine (282)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (74)
  • Surgery (107)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)